Application Detail
Description of Medical Service
Dinutuximab beta (monoclonal antibody therapy) used in conjunction with combination chemotherapy in patients who have experienced a primary relapse or are refractory to treatment. This treatment is currently funded for patients who achieve at least a partial response to induction chemotherapy and this application is seeking an extension of funding to include the primary relapse or refractory population.Description of Medical Condition
Neuroblastoma is the most frequent cancer in children less than one year old. About half of patients with neuroblastoma are classified as having high-risk disease. The treatment is intended for patients with high-risk neuroblastoma who experience primary (first) relapse or are refractory (do not respond) to treatment.Reason for Application
Change to existing listing - Highly specialised therapies - National Health Reform Agreement AddendumMedical Service Type
Therapeutic technologyPrevious Application Number/s
1625Associated Documentation
Application Summary and PICO Set
Application Summary (PDF 136 KB)Application Summary (Word 27 KB)
PICO Set (PDF 1511 KB)
PICO Set (Word 557 KB)
Consultation Survey
Consultation SurveyPASC Consultation
Bypassing PASC
MSAC Consultation
MSAC consultation closes Friday 14 February 2025
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process